Compare VOC & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VOC | NXTC |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.8M | 39.1M |
| IPO Year | N/A | 2019 |
| Metric | VOC | NXTC |
|---|---|---|
| Price | $2.91 | $2.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 55.1K | ★ 125.1K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 12.46% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $22,378,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.60 | $1.55 |
| 52 Week High | $3.84 | $15.74 |
| Indicator | VOC | NXTC |
|---|---|---|
| Relative Strength Index (RSI) | 51.56 | 32.62 |
| Support Level | $2.81 | $1.55 |
| Resistance Level | $3.11 | $10.81 |
| Average True Range (ATR) | 0.08 | 0.33 |
| MACD | 0.03 | 0.29 |
| Stochastic Oscillator | 89.16 | 64.81 |
VOC Energy Trust is a statutory trust. It is created to acquire and hold a term net profits interest for the benefit of the Trust unitholders. The underlying properties include VOC Brazos' net interests which are located in the states of Kansas and Texas. The trust is entitled to receive the net proceeds from the sale of production of oil and natural gas attributable to the underlying properties. The business and affairs of the Trust are managed by the Trustee, and neither VOC Brazos nor any of its affiliates has the ability to manage or influence the operations of the Trust. It operates in a single operating and reportable segment.
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.